Management 1x1 Series: James Lanthier, CEO of Mindset Pharma - The Future of Psychedelics

Grizzle Pod: Thematic Growth Investing

English - October 31, 2022 18:08 - 28 minutes - 26.4 MB - ★★★★★ - 3 ratings
Investing Business Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Management 1x1 Series: Alberto Arias, Chairman of Largo. Vanadium - The Battery and Energy Efficiency Metal

Next Episode: Grizzle Battery Metals 1x1 Conference 2022

In our second episode of the Management 1x1 Series we are thrilled to have James Lanthier, CEO of Mindset Pharma join us. Mindset is one of the world's leading companies in the field of psychedelic medicines to treat neurological and psychiatric disorders. James brings a wealth of insight to the pod and breaks down the big picture of the true disruption happening in the psychedelics industry - enjoy the interview.

Segments:

0:40 What's the opportunity set and how disruptive are psychedelics?

4:58 Where are we in terms of cultural and medical acceptance of psychedelics?

9:26 Mindset Pharma's science driven focus in the sector

13:42 Understanding the process of enhancing 1st generation psychedelic drugs.

18:45 Mindset's partnership with big pharma - Otsuka Pharmaceuticals, understanding the validation and importance for the industry.

23:40 The asset light nature of the business model.

25:13 The outlook for the psychedelics industry and what separates winners from losers?